1. Home
  2. NMRA vs EIC Comparison

NMRA vs EIC Comparison

Compare NMRA & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • EIC
  • Stock Information
  • Founded
  • NMRA 2019
  • EIC N/A
  • Country
  • NMRA United States
  • EIC United States
  • Employees
  • NMRA N/A
  • EIC N/A
  • Industry
  • NMRA
  • EIC Finance/Investors Services
  • Sector
  • NMRA
  • EIC Finance
  • Exchange
  • NMRA Nasdaq
  • EIC Nasdaq
  • Market Cap
  • NMRA 287.6M
  • EIC 287.1M
  • IPO Year
  • NMRA 2023
  • EIC 2019
  • Fundamental
  • Price
  • NMRA $1.28
  • EIC $15.23
  • Analyst Decision
  • NMRA Buy
  • EIC Strong Buy
  • Analyst Count
  • NMRA 8
  • EIC 1
  • Target Price
  • NMRA $10.14
  • EIC $17.50
  • AVG Volume (30 Days)
  • NMRA 1.3M
  • EIC 262.3K
  • Earning Date
  • NMRA 03-03-2025
  • EIC 02-20-2025
  • Dividend Yield
  • NMRA N/A
  • EIC 15.75%
  • EPS Growth
  • NMRA N/A
  • EIC N/A
  • EPS
  • NMRA N/A
  • EIC 1.97
  • Revenue
  • NMRA N/A
  • EIC $46,223,036.00
  • Revenue This Year
  • NMRA N/A
  • EIC $39.61
  • Revenue Next Year
  • NMRA N/A
  • EIC $27.28
  • P/E Ratio
  • NMRA N/A
  • EIC $7.75
  • Revenue Growth
  • NMRA N/A
  • EIC 72.79
  • 52 Week Low
  • NMRA $1.26
  • EIC $14.78
  • 52 Week High
  • NMRA $17.19
  • EIC $16.75
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 26.96
  • EIC 33.89
  • Support Level
  • NMRA $1.26
  • EIC $15.36
  • Resistance Level
  • NMRA $1.48
  • EIC $16.05
  • Average True Range (ATR)
  • NMRA 0.13
  • EIC 0.20
  • MACD
  • NMRA 0.08
  • EIC -0.07
  • Stochastic Oscillator
  • NMRA 4.44
  • EIC 2.38

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.

Share on Social Networks: